Skip to main content
Top
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

Amyloid-like fibrils are not detected in non-small cell lung cancer tissue samples

Authors: Luiz Henrique de Lima Araújo, Luciana W. Pinto, Luciene F. Schluckebier, Joyce L. de Moraes, Paulo A. Faria, Emanuela Moraes, Carlos G. Ferreira, Cinthya Sternberg

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

Some proteins, canonically not associated with amyloid diseases, can aggregate into amyloid-like fibrils under special conditions. Our group hypothesized that stressful cancer microenvironment might induce the formation of insoluble deposits of p53 mutant protein. A cohort of 28 non-small cell lung cancer (NSCLC) patients was used to test the aforementioned hypothesis. Tumor specimens were assessed for TP53 mutations using DNA sequencing and for amyloid formation by Congo red staining. TP53 mutations were present in 57% of patients, whereas no amyloid deposits were detected in tissue sections under polarized light microscopy. Mutant p53 proteins are not associated with the appearance of amyloid-like fibrils in NSCLC samples, and DNA sequencing remains the standard method to detect such abnormality.
Literature
1.
go back to reference Fersht AR. A guide to enzyme catalysis and protein folding. In: Fersht A, editor. Structure and mechanism in protein science. New York: W.H. Freeman & Co Ltd; 1999. p. 508–539. Fersht AR. A guide to enzyme catalysis and protein folding. In: Fersht A, editor. Structure and mechanism in protein science. New York: W.H. Freeman & Co Ltd; 1999. p. 508–539.
2.
go back to reference Horwich A. Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. J Clin Invest. 2002;110:1221–32.PubMed Horwich A. Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. J Clin Invest. 2002;110:1221–32.PubMed
3.
go back to reference Ishimaru D, Andrade LR, Teixeira LSP, et al. Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry. 2003;42:9022–7.PubMedCrossRef Ishimaru D, Andrade LR, Teixeira LSP, et al. Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry. 2003;42:9022–7.PubMedCrossRef
4.
go back to reference Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol. 2010;2(6):a000919.PubMedCrossRef Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol. 2010;2(6):a000919.PubMedCrossRef
5.
go back to reference Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, editors. Histological typing of lung and pleural tumours. In: World Health Organization international histological classification of tumours. 3rd ed. Geneva: Springer-Verlag; 1999. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, editors. Histological typing of lung and pleural tumours. In: World Health Organization international histological classification of tumours. 3rd ed. Geneva: Springer-Verlag; 1999.
6.
go back to reference Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010;20(5):299–309.PubMedCrossRef Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010;20(5):299–309.PubMedCrossRef
7.
go back to reference Vowles GH, Francis RJ. Amyloid. In: Bancroft J., Gamble M. Theory and practice of histological techniques. London: Churchill Livingstone Elsevier; 2002. p. 303–24. Vowles GH, Francis RJ. Amyloid. In: Bancroft J., Gamble M. Theory and practice of histological techniques. London: Churchill Livingstone Elsevier; 2002. p. 303–24.
8.
go back to reference Westermark P, Benson MD, Buxbaum JN, et al. Nomenclature committee of the international society of amyloidosis. A primer of amyloid nomenclature. Amyloid. 2007;14(3):179–83.PubMedCrossRef Westermark P, Benson MD, Buxbaum JN, et al. Nomenclature committee of the international society of amyloidosis. A primer of amyloid nomenclature. Amyloid. 2007;14(3):179–83.PubMedCrossRef
9.
go back to reference Picken MM. New Insights into systemic amyloidosis: the importance of type diagnosis. Curr Opinion Nephrol Hypertens. 2007;16(3):196–203.CrossRef Picken MM. New Insights into systemic amyloidosis: the importance of type diagnosis. Curr Opinion Nephrol Hypertens. 2007;16(3):196–203.CrossRef
10.
go back to reference Picken MM, Hazenberg BPC, Obici L. Report from the diagnostic interactive session. In: Skinner M, Berk JL, Connors LH, et al., editors. XIth international symposium on amyloidosis. Boca Raton, FL: CRC Press; 2007. p. 377–82. Picken MM, Hazenberg BPC, Obici L. Report from the diagnostic interactive session. In: Skinner M, Berk JL, Connors LH, et al., editors. XIth international symposium on amyloidosis. Boca Raton, FL: CRC Press; 2007. p. 377–82.
11.
go back to reference Picken MM. Amyloidosis—where are we now and where are we heading? Arch Pathol Lab Med. 2010;134(4):545–51.PubMed Picken MM. Amyloidosis—where are we now and where are we heading? Arch Pathol Lab Med. 2010;134(4):545–51.PubMed
12.
go back to reference Fändrich M. On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell Mol Life Sci. 2007;64(16):2066–78.PubMedCrossRef Fändrich M. On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell Mol Life Sci. 2007;64(16):2066–78.PubMedCrossRef
13.
go back to reference Levy CB, Stumbo AC, Ano Bom AP, Portari EA, Carneiro Y, Silva JL, De Moura-Gallo CV. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors. Int J Biochem Cell Biol. 2011;43(1):60–4.PubMedCrossRef Levy CB, Stumbo AC, Ano Bom AP, Portari EA, Carneiro Y, Silva JL, De Moura-Gallo CV. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors. Int J Biochem Cell Biol. 2011;43(1):60–4.PubMedCrossRef
Metadata
Title
Amyloid-like fibrils are not detected in non-small cell lung cancer tissue samples
Authors
Luiz Henrique de Lima Araújo
Luciana W. Pinto
Luciene F. Schluckebier
Joyce L. de Moraes
Paulo A. Faria
Emanuela Moraes
Carlos G. Ferreira
Cinthya Sternberg
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9915-y

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.